IP Library Granted Patent US 9,989,523
Granted Patent B2
US 9,989,523 · App. 14/942,921 · Granted Jun 5, 2018

Kits, compositions and methods for detecting a biological condition

Inventors: Harvey Lee Kasdan (Jerusalem, IL); Julien Meissonnier (Jerusalem, IL); Yoav Zuta (Jerusalem, IL); Bruce Davis (Jerusalem, IL); Micha Rosen (Jerusalem, IL); Yael Himmel (Jerusalem, IL); Yehoshua Broder (Jerusalem, IL)
Assignee: LEUKODX LTD.
G01N33/5302B01L3/502B01L3/5027B01L3/50273B01L3/502715G01N33/5091G01N33/54386G01N33/569G01N33/56972G01N33/582G01N33/68G01N33/6872B01L2200/025B01L2200/10B01L2300/041B01L2300/0654B01L2300/0816B01L2300/0867B01L2300/0877B01L2300/0883B01L2300/123B01L2300/18B01L2400/0406B01L2400/0481G01N2333/70535G01N2333/70596G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,989,523
App. No.
14/942,921
Granted
Jun 5, 2018
Kind
B2
Abstract

The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.

Claims (36)

1. A test cartridge for analyzing a sample from a subject, the test cartridge comprising:

a) a sample composition chamber adapted for receiving the sample from the subject;

b) a first blister comprising an antibody mixture comprising fluorescently tagged target antibodies and fluorescently tagged control antibodies;

c) a second blister comprising a cell lysis reagent;

d) a third blister comprising beads comprising a fluorescent tag, wherein the fluorescent tag is different than those of the target antibodies and control antibodies;

d) a treatment compartment adapted for fluid mixing, wherein the treatment compartment is coupled to the sample composition chamber, the first blister, the second blister, and the third blister via one or more transfer elements, wherein the one or more transfer elements are microfluidic channels that allow fluid communication between the treatment compartment and (1) the sample composition chamber, (2) the first blister, (3) the second blister, and (4) the third blister; and

e) an evaluation chamber fluidly connected to the treatment chamber and comprising a reading zone, wherein the reading zone allows the sample to be analyzed as it passes therethrough.

2. The test cartridge of claim 1 , wherein the beads comprise a second fluorescent tag different from the fluorescent tag.

3. The test cartridge of claim 1 , wherein the target antibodies are CD64 antibodies and wherein the control antibodies are CD163 antibodies.

4. The test cartridge of claim 1 , further comprising a pump or an air blowing element coupled to the treatment compartment.

5. The test cartridge of claim 4 , wherein the pump is a bellow pump.

6. The test cartridge of claim 1 , wherein a volume of any of the blisters is from about 1 microliter to 1000 microliters.

7. The test cartridge of claim 1 , wherein a volume of the sample is about 50 microliters or smaller.

8. The test cartridge of claim 1 , wherein the one or more transfer elements are designed to allow mixing of fluid.

9. The test cartridge of claim 8 , wherein the one or more transfer elements has a tortuous shaped channel.

10. The microfluidic cartridge of claim 1 , wherein the fluorescently tagged beads comprise Starfire Red.

11. The test cartridge of claim 1 , wherein the blood sample comprises erythrocytes or leukocytes.

12. The microfluidic cartridge of claim 1 , wherein the cell lysis reagent comprises ammonium chloride.

13. The microfluidic cartridge of claim 1 , wherein the antibodies are murine monoclonal antibodies.

14. A Cartridge Handling Unit (CHU) for providing an indication of a biological condition in a subject, the CHU adapted to receive a test cartridge and pre-programmed to perform at least the following steps:

a) pressing a first blister of the test cartridge thereby releasing an antibody mixture and permitting it to contact with the sample, wherein the antibody mixture comprises fluorescently tagged target antibodies and fluorescently tagged control antibodies;

b) allowing the sample and the antibody mixture to contact for a predetermined time thereby fluorescently tagging cells in the sample;

c) pressing a second blister of the test cartridge thereby releasing beads comprising a fluorescent tag to contact the sample and the antibody mixture, wherein the fluorescent tag is different than those of the target antibodies and control antibodies;

d) flowing the fluorescently tagged cells and the fluorescently tagged beads through a reading zone;

e) exciting the fluorescent tags of the beads and of the antibodies;

f) measuring fluorescent signals of the fluorescently tagged cells and of the fluorescently tagged beads simultaneously;

g) analyzing fluorescent emission signatures of the fluorescently tagged cells, wherein analysis is done on individual fluorescently tagged cells; and

h) providing an indication of the biological condition in the subject, wherein the indication is provided using the analysis.

15. The CHU of claim 14 , wherein the beads comprise a second fluorescent tag different from the fluorescent tag.

16. The CHU of claim 14 , wherein the target antibodies are CD64 antibodies and wherein the control antibodies are CD163 antibodies.

17. The CHU of claim 14 , wherein the CHU is pre-programmed to perform the steps in less than 30 minutes.

18. The CHU of claim 14 , wherein the CHU is pre-programmed to press a third blister of the test cartridge thereby releasing a cell lysis reagent and permitting the cell lysis reagent to contact the sample and the antibody mixture.

19. The CHU of claim 18 , wherein pressing the third blister occurs after pressing the first blister and before pressing the second blister.

20. The CHU of claim 14 , wherein the CHU is pre-programmed to determine a type of the blood cells.

21. The CHU of claim 14 , wherein a volume of any of the blisters is from about 1 microliter to 1000 microliters.

22. The CHU of claim 14 , wherein a volume of the sample is about 50 microliters or smaller.

Assignments (2)
CHANGE OF NAME Recorded May 7, 2020
From: KASDAN, HARVEY LEE; MEISSONNIER, JULIEN; ZUTA, YOAV; DAVIS, BRUCE; ROSEN, MICHA; HIMMEL, YAEL; BRODER, YEHOSHUA
To: ACCELLIX LTD.
Reel/Frame 052595/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2016
From: KASDAN, HARVEY LEE; MEISSONNIER, JULIEN; ZUTA, YOAV; DAVIS, BRUCE; ROSEN, MICHA; HIMMEL, YAEL; BRODER, YEHOSHUA
To: LEUKODX LTD.
Reel/Frame 037649/0492 →
Continuity (4)
Continuation 14571906 · Dec 16, 2014
Continuation 14296317 · Jun 4, 2014
Division 13716246 · Dec 17, 2012
Related Publication 20160146793A1 · May 26, 2016